Who said money doesn’t grow on trees?

Published 07-OCT-2019 11:44 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

In mid-September Finfeed noted that CropLogic Limited’s (ASX:CLI) Hemp Trial Farm in Central Oregon had entered the fourth stage of development.

At that stage the plants had flowered well and were at an advanced stage of growth as the company prepared for its October harvest.

Management of the award-winning global agronomy, farm management and agtech company announced on Monday morning that it was on track for the harvest of a high-quality crop which had met all of the regulatory requirements under Oregonian law.

Testing by a third party ORELAP (Oregon Environmental Laboratory Accreditation Program) accredited lab, one of only some 21 labs authorised by Oregon Department of Agriculture (ODA) to perform Industrial Hemp compliance testing, has confirmed that all fields under the Hemp Trial Farm have a THC level below the maximum requirement for them to be treated as industrial hemp.

Under Oregonian law, hemp fields need to be tested by an ODA authorised lab to ensure delta-9 levels are below .35%, a process commonly called in the industry ‘compliance testing’.

Fields at CropLogic’s Hemp Trial Farm in central Oregon operated by its wholly owned subsidiary LogicalCropping, recorded results from zero (below limit of quantitation) to .0738% of delta-9 THC, well below the required maximum of .35%.

This means that all fields are compliant for them to be treated as industrial hemp and the company has been advised that this lab will be lodging these fields as such with the ODA.

Discussing the importance of regulatory approval, Chief Executive James Cooper-Jones said, "This is another significant milestone for the Hemp Trial Farm.

"Once again, the combination of good genetics, sourced through the hemp expertise resourced by LogicalCropping, combined with growing methods developed using CropLogic’s agronomy, farm management and agtech expertise has worked in the Trial Farm’s favour."

A combine harvester, swather (windrower) attachment and swather (windrower) arriving on site ahead of harvest.

Harvest in final stages

With compliance testing complete, management has also made progress on the logistics side with much of the large machinery on site.

Management confirmed that CropLogic’s expertise in agronomy and farm management had translated into robust growing methods, suggesting that it should be well placed to meet harvest expectations which implied the generation of substantial revenues for the company.

The company has also positioned itself to generate revenues in years to come from showcasing its farm management and technical expertise in the hub of a major agricultural region.

While management hasn’t committed to establishing a hemp farming business, it said that the upcoming harvest would include different methodologies at the Hemp Trial Farms to test their ‘application into hemp farming at scale and potential use in any eventual expansion.’

Some fairly predictable profit-taking occurred in August, after the group’s shares had increased 500% in five months, but the stock showed resilience last week, gaining 5% in the face of a global downturn in equities markets.

In the first hour of trading on Monday, the company’s shares traded as high as 6.7 cents, up 8% on Friday’s close.

CropLogic’s shares are now up approximately 25% on a month-on-month basis.

Given that this is the first time the company has traded at today’s levels since the August sell-off, investors may be targeting the stock ahead of the much anticipated harvest news, at which point a significant degree of revenue transparency is likely to have the number crunchers attributing a much firmer ‘with confidence’ valuation to the stock.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X